Mandate

Vinge assisted Industrifonden in connection with the sale of shares in Oncopeptides AB (publ) through an accelerated bookbuilding process

August 17, 2018

In total, 1,2 million shares were placed at a price of SEK 148 per share, corresponding to a total value of approximately SEK 178 million.

Following the transaction, Industrifonden holds approximately 23.67% of the shares in Oncopeptides.
 
Vinge’s team consisted of Dain Hård Nevonen, Rikard Lindahl and Sofie Bjärtun.

Related

Vinge advises KEYTO Group in connection with the acqusition of Säkra Larm

KEYTO Group continues to broaden its home services offering as Säkra Larm joins the Group, establishing home security as a new business vertical within KEYTO. The addition marks another important step in KEYTO's ambition to become the leading one-stop destination for services connected to the home.
September 24, 2026

Vinge has advised Ingrid Capacity in connection with the formation of a strategic partnership with Mirova for a strategic partnership for a large-scale BESS portfolio in the Nordics

Ingrid Capacity and Mirova, an affiliate of Natixis Investment Managers dedicated to sustainable investment, announce a cross-border partnership of two BESS projects totalling 145 MW/290 MWh in Sweden and Finland. Vinge has advised Ingrid Capacity in connection with the formation of the partnership.
September 24, 2026

Vinge advises the financing banks in connection with Verdane and Telenor’s partnership in Telenor Connexion

Vinge has advised a syndicate of Nordic and Northern European banks connection with the financing of Verdane and Telenor’s new partnership relating to Telenor Connexion. Under the partnership, Verdane and Telenor will jointly invest in Telenor Connexion, a leading provider of IoT solutions. The transaction was completed on 10 September 2026 and values Telenor Connexion at SEK 7.5 billion.
September 23, 2026